Literature DB >> 20591979

High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel.

Marlene Troch1, Oskar Koperek, Christian Scheuba, Karin Dieckmann, Martha Hoffmann, Bruno Niederle, Markus Raderer.   

Abstract

CONTEXT: Anaplastic thyroid carcinoma (ATC) is a rare but aggressive solid tumor with a very short survival time even with multimodality treatment. In view of in vitro data and the high rate of p53 mutations in ATC, we have used combined treatment with external beam radiation and docetaxel.
OBJECTIVE: The objective was to analyze the activity using radiation plus docetaxel.
DESIGN: The design was a retrospective analysis.
SETTING: The study was performed in a referral center of a university hospital. PATIENTS: A total of six patients with ATC were treated at our institution. INTERVENTION: Treatment consisted of standard external beam radiation of 60.0 Gy in 30 fractions along with docetaxel at a flat dose of 100 mg absolute every 3 wk for a total of six cycles starting within the first week of radiation. OUTCOME MEASURE: The outcome measure included clinical response and survival.
RESULTS: Five patients completed radiochemotherapy. One patient has completed radiation but is still on treatment with docetaxel. Four patients achieved complete remission and two partial response. During radiation therapy, four patients developed severe mucositis/stomatitis and two dermatitis, necessitating hospitalization. Two patients developed pneumonia and one urinary tract infection. All patients were hospitalized for a median of 17 d (range, 4-40 d) because of toxicites. After a median follow up of 21.5 months (range, 2-40 months), five patients are alive.
CONCLUSION: The preliminary data suggest that the combination of radiation and concomitant docetaxel is highly effective in patients with ATC. However, a formal phase II study is needed to assess the therapeutic potential of this combination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591979     DOI: 10.1210/jc.2009-2827

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

2.  Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

Authors:  Iwao Sugitani; Akira Miyauchi; Kiminori Sugino; Takahiro Okamoto; Akira Yoshida; Shinichi Suzuki
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 3.  Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Authors:  Pamela Jo Harris; Keith C Bible
Journal:  Expert Opin Investig Drugs       Date:  2011-10       Impact factor: 6.206

Review 4.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Authors:  Keith C Bible; Mabel Ryder
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

5.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

6.  Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Authors:  R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 8.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

9.  Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.

Authors:  Ayman Oweida; Andy Phan; Benjamin Vancourt; Tyler Robin; Mohammad K Hararah; Shilpa Bhatia; Dallin Milner; Shelby Lennon; Laura Pike; David Raben; Bryan Haugen; Nikita Pozdeyev; Rebecca Schweppe; Sana D Karam
Journal:  Thyroid       Date:  2018-06       Impact factor: 6.568

10.  Approach to the patient with anaplastic thyroid carcinoma.

Authors:  Robert C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.